Cyntellect, Inc. Appoints David Voris Chief Financial Officer

SAN DIEGO, Nov. 13 /PRNewswire/ -- Cyntellect, Inc., a life sciences company pioneering the development and commercialization of laser-based live-cell manipulation systems, announced today that it has appointed David Voris as its Vice President of Finance & Administration and Chief Financial Officer. Mr. Voris’ appointment was effective November 5th, 2007.

Mr. Voris brings with him more than twenty-two years of experience as a financial professional, primarily with companies in the life sciences arena. Most recently, he served as the Chief Financial Officer of SynergEyes, a leader in the development and commercialization of hybrid contact lenses. David also served as Chief Financial Officer of Laser Diagnostic Technologies from 1999 until its successful sale to Carl Zeiss Meditec in 2004. During his career, David has held various positions in finance and operations with companies including Alaris Medical Systems and Metracor Technologies. He began his career at Deloitte & Touche as a CPA and received his undergraduate degree from Arizona State University.

“David is an excellent addition to the Cyntellect team and we expect his leadership experience in the areas of finance and operations with growth stage life science companies will contribute significantly to Cyntellect as we expand our operations and increase our commercial efforts,” stated Fred Koller, Ph.D., Cyntellect’s President and Chief Executive Officer.

About Cyntellect

Cyntellect, Inc. is a life sciences company committed to revolutionizing the use of living cells in life science research and cellular therapy. The company combines expertise in high-speed cell imaging and laser-based manipulation to develop products that enable novel cell imaging, purification, and transfection capabilities to enhance the productivity of laboratory research, recombinant protein production, high-content cellular assays, functional genomics and proteomics, and cell purification, including processing of cells for therapeutic transplantation. For additional information please visit the company’s web site at www.cyntellect.com.

CONTACT: Jim Linton, Ph.D., Chief Business Officer of Cyntellect, Inc.,
+1-858-450-7060, jlinton@cyntellect.com

Web site: http://www.cyntellect.com/

MORE ON THIS TOPIC